Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human SCN8A Antibodies:
anti-Rat (Rattus) SCN8A Antibodies:
anti-Mouse (Murine) SCN8A Antibodies:
Go to our pre-filtered search.
Mammalian Monoclonal SCN8A Primary Antibody for ISt, IHC - ABIN1304841
Rush, Wittmack, Tyrrell, Black, Dib-Hajj, Waxman: Differential modulation of sodium channel Na(v)1.6 by two members of the fibroblast growth factor homologous factor 2 subfamily. in The European journal of neuroscience 2006
Show all 35 Pubmed References
Human Monoclonal SCN8A Primary Antibody for IF, WB - ABIN2476430
Ogiwara, Miyamoto, Morita, Atapour, Mazaki, Inoue, Takeuchi, Itohara, Yanagawa, Obata, Furuichi, Hensch, Yamakawa: Nav1.1 localizes to axons of parvalbumin-positive inhibitory interneurons: a circuit basis for epileptic seizures in mice carrying an Scn1a gene mutation. in The Journal of neuroscience : the official journal of the Society for Neuroscience 2007
SCN8A mutation is not only associated with epileptic encephalopathy, but also can be the pathogenic cause of some benign phenotypes, such as BFIS/ICCA (show PRRT2 Antibodies), especially the inherited mutations.
This study demonstrated that SCN8A - I1327V is a gain-of-function mutation with altered features that are predicted to increase neuronal excitability and seizure susceptibility. Phenytoin is an effective inhibitor of the mutant channel and may be of use in treating patients with gain-of-function mutations of SCN8A.
Epilepsy-associated mutations in the voltage-gated sodium channel Nav1.6, but not Nav1.1 (show SCN1A Antibodies), upregulate resurgent currents; cannabidiol preferentially targets these currents.
Either the FGF14 (show FGF14 Antibodies)(V160A) or the FGF14 (show FGF14 Antibodies)(K74A/I76A) mutation was sufficient to abolish the FGF14 (show FGF14 Antibodies)-dependent regulation of peak transient Na(+) currents and the voltage-dependent activation and steady-state inactivation of Nav1.6; but only V160A with a concomitant alanine mutation at Tyr (show TYR Antibodies)-158 could impede FGF14 (show FGF14 Antibodies)-dependent modulation of the channel fast inactivation.
we report an infant and his father with early onset focal epileptic seizures but without cognitive or neurological impairment in whom next generation sequence analysis identified a heterozygous mutation (c.5630A > G, p. (Asn1877Ser)) in the SCN8A gene
the calpain-dependent cleavage of Nav1.6 channels expressed in human embryonic kidney (HEK) 293 cells caused the upregulation of I(NaP)
Our study establishes SCN8A as a novel gene in which a recurrent mutation causes BFIS/ICCA (show PRRT2 Antibodies), expanding the clinical-genetic spectrum of combined epileptic and dyskinetic syndromes.
Human Nav1.6 channels generate larger resurgent currents than human Nav1.1 (show SCN1A Antibodies) channels, but the SCN4B (show SCN4B Antibodies)-derived Navbeta4 (show SCN4B Antibodies) peptide does not protect either isoform from use-dependent reduction.
These data strengthen previous findings linking gain-of-function mutations of SCN8A with EIEE and demonstrate the importance of functional testing in establishing the pathogenicity of de novo mutations.
Expression profiling of SCN8A and NDUFC2 (show NDUFC2 Antibodies) genes in colorectal carcinoma is reported. There was no NDUFC2 (show NDUFC2 Antibodies) differential expression in colorectal carcinoma.
that loss of Scn8a leads to altered thalamic reticular nucleus cell intrinsic excitability and a failure in recurrent RT synaptic inhibition
The data of this study support the view that gain-of-function mutations of SCN8A lead to pathogenic alterations in brain function contributing to encephalopathy.
The clinical phenotype of the severe hypomorphic sodium channel gene SCN8A mutant expands the spectrum of Scn8a disease to include a recessively inherited, chronic and progressive movement disorder.
the presences of Nav1.1 (show SCN1A Antibodies), Nav1.6, Navbeta1 and Navbeta3 mRNA and their reduced levels in rat SAN during aging.
This study demonstrates that Nav channel expression in lumbar motoneurons is altered after SCI, and it shows a tight relationship between the calpain-dependent proteolysis of Nav1.6 channels, the upregulation of I(NaP (show CTNNBL1 Antibodies)) and spastici
the role of Nav1.6 in general anesthesia using two mouse mutants with reduced activity of Nav1.6, was examined.
observed increased hippocampal pyramidal cell excitability in heterozygous and homozygous Scn8a-R1627H mutants, and decreased interneuron excitability in heterozygous Scn8a-R1627H mutants.
The data support a model where ankyrinG (show ANK3 Antibodies)-binding is required for preferential Nav1.6 insertion into the axon initial segment plasma membrane during development.
the degenerating muscle mutation is a loss of function mutation of scn8a
N1768D mutation of SCN8A is sufficient to induce seizures and SUDEP in knock-in mice.
This gene encodes a member of the sodium channel alpha subunit gene family. The encoded protein forms the ion pore region of the voltage-gated sodium channel. This protein is essential for the rapid membrane depolarization that occurs during the formation of the action potential in excitable neurons. Mutations in this gene are associated with mental retardation, pancerebellar atrophy and ataxia. Alternate splicing results in multiple transcript variants.
hNa6/Scn8a voltage-gated sodium channel
, sodium channel protein type 8 subunit alpha
, voltage-gated sodium channel subunit alpha Nav1.6
, Na+ channel
, peripheral nerve protein type 4
, sodium channel 6
, sodium channel protein type VIII subunit alpha
, sodium channel voltage-gated type VIII alpha polypeptide
, sodium channel, voltage-gated, type 8, alpha polypeptide
, sodium channel, voltage-gated, type 8, alpha subunit
, sodium channel, voltage-gated, type VIII, alpha polypeptide
, ataxia 3